A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2001
10/17/2001	EP1144443A2 Human membrane transport proteins
10/17/2001	EP1144435A2 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144431A2 16-hydroxyestratrienes as selective estrogens
10/17/2001	EP1144409A2 Phenyl urea and phenyl thiourea derivatives
10/17/2001	EP1144405A1 Triazole compounds with dopamine-d3-receptor affinity
10/17/2001	EP1144403A1 Substitued pyrazoles as p38 kinase inhibitors
10/17/2001	EP1144402A2 Substituted oximes and hydrazones as neurokinin antagonists
10/17/2001	EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
10/17/2001	EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor
10/17/2001	EP1144390A2 Kinase inhibitors
10/17/2001	EP1144388A1 Acyl derivatives which treat vla-4 related disorders
10/17/2001	EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
10/17/2001	EP1144386A1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
10/17/2001	EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/17/2001	EP1144364A2 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144361A1 Method for reducing 3-dimethylamino-2-phenylpropion-acid ethyl ester-content in solutions of 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylic acid ethyl ester
10/17/2001	EP1144305A1 NOVEL sPLA 2 INHIBITORS
10/17/2001	EP1143984A1 Egg anti-inflammatory composition and method of treating and preventing inflammation
10/17/2001	EP1143965A1 Carbocyclic potassium channel inhibitors
10/17/2001	EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers
10/17/2001	EP0983265A4 Endothelin receptor antagonists
10/17/2001	EP0942911B1 Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds
10/17/2001	EP0808103A4 Protein hydroxylation inhibitors for fibroproliferative disorders
10/17/2001	EP0796251B1 Uracil derivatives
10/17/2001	CN1318056A Pyridinum derivatives for management of aging-related and diabetic vascular complications, process for their prepn. and therepeutic uses thereof
10/17/2001	CN1318054A Novel compounds
10/17/2001	CN1318053A Cyclopentanoue dihydropyridine compounds useful as potassium channel openers
10/17/2001	CN1318052A Arylpiperazine derivatives useful as uroselective alpha-adrenoceptor blockers
10/17/2001	CN1317964A Composition
10/17/2001	CN1317962A Remedies for renal failure
10/17/2001	CN1072939C Medicament for treating primary glomerular disease
10/17/2001	CN1072935C Prepn. method for medical compsns. contg. aza-steroid compound for treating prostatic hyperplasia
10/17/2001	CN1072932C Method of preventing emesis and treating sexual dyfunction using tetra hydrobenz [CD] indole-6-carboxamides
10/16/2001	US6303789 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
10/16/2001	US6303643 Therapy of migraine headache, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, presbyopia, ischemic pain, spasticity, diarrhea, nasal congestion, and urinary incontinence by administering benzothiazole derivative
10/16/2001	US6303637 For therapy of autoimmune disease, prophylaxis of resistance to transplantation or transplantation rejection of organs or tissues; suppressing immune system
10/16/2001	US6303601 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
10/16/2001	US6303126 Treatment of fibrosis by HGF
10/11/2001	WO2001074901A2 Polynucleotides and polypeptides, their use in diagnosis and treatment of cardiac, renal or inflammary disease
10/11/2001	WO2001074896A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	WO2001074835A1 O-glucosylated benzamide sglt2 inhibitors and method
10/11/2001	WO2001074834A1 O-aryl glucoside sglt2 inhibitors and method
10/11/2001	WO2001074806A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	WO2001074775A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001	WO2001074763A1 Aryl and heteroaryl sulfonates
10/11/2001	WO2001074390A2 The use of a calcium channel blocker for treating renal disorders
10/11/2001	WO2001074369A1 Divided dose therapies with vascular damaging activity
10/11/2001	WO2001074334A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
10/11/2001	WO2001028566B1 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
10/11/2001	WO2001025269A3 Human g-protein coupled receptor
10/11/2001	WO2001025210A3 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
10/11/2001	WO2001019826A3 Triazolopyrimidine derivatives
10/11/2001	WO2000064421A3 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
10/11/2001	WO2000017176A3 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
10/11/2001	US20010029304 Cyclopentane heptan (ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
10/11/2001	US20010029264 In mixture with vitamin e, dimethylisosorbide, citric acid and polyoxyethylene glycol
10/11/2001	US20010028899 Composition for supprssing cellular fibrousing and method for preparing an extract from loquat seeds
10/11/2001	DE10015866A1 Aryl- und Heteroarylsulfonate Aryl and Heteroarylsulfonate
10/11/2001	CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001	CA2404545A1 Aryl and heteroaryl sulfonates
10/11/2001	CA2404376A1 O-glucosylated benzamide sglt2 inhibitors and method
10/11/2001	CA2404373A1 O-aryl glucoside sglt2 inhibitors and method
10/11/2001	CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	CA2403950A1 Treatment of renal disorders
10/11/2001	CA2403886A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
10/11/2001	CA2403600A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	CA2402078A1 Divided dose therapies with vascular damaging activity
10/10/2001	EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents
10/10/2001	EP1142875A1 Cinnamamide derivatives and drug compositions containing the same
10/10/2001	EP1142584A1 Compositions for treating frequent urination and urinary incontinence
10/10/2001	EP1141728A1 Kidney disease detection and treatment
10/10/2001	EP1141339A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
10/10/2001	EP1141332A1 Human cyclic nucleotide pdes
10/10/2001	EP1141325A1 Ikk3 kinase
10/10/2001	EP1141286A1 Cytokine receptor chain
10/10/2001	EP1141278A2 Therapeutic phosphodiesterase inhibitors
10/10/2001	EP1141274A2 Soluble receptor br43x2 and methods of using them for therapy
10/10/2001	EP1141266A2 Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof
10/10/2001	EP1141240A1 Use of cd40 engagement to alter t cell receptor usage
10/10/2001	EP1141027A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
10/10/2001	EP1141015A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001	EP1141014A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001	EP1140989A1 Alpha(v) beta(6) integrin inhibitors
10/10/2001	EP1140981A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
10/10/2001	EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001	EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001	EP1140945A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
10/10/2001	EP1140938A2 High affinity inhibitors for target validation and uses thereof
10/10/2001	EP1140923A1 Method for preparing (r)- (+) -3 1- 2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl]- 4-phenylpiperidin -4-yl -1,1- dimethylurea, its salts solvates and/or hydrates
10/10/2001	EP1140908A1 Triazole compounds with dopamine-d3-receptor affinity
10/10/2001	EP1140907A1 Triazole compounds with dopamine-d3-receptor affinity
10/10/2001	EP1140889A2 Compounds and methods for modulation of estrogen receptors
10/10/2001	EP1140876A1 Morpholinone and morpholine derivatives and uses thereof
10/10/2001	EP1140867A1 New beta-amide and beta-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists
10/10/2001	EP1140859A2 (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
10/10/2001	EP1140849A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
10/10/2001	EP1140836A1 Amide compounds
10/10/2001	EP1140784A2 Ion channel modulating agents
10/10/2001	EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp

1 ... 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 ... 562